Related Experiment Video
Updated: Jun 18, 2026

Molecular Analysis of Endothelial-mesenchymal Transition Induced by Transforming Growth Factor-β Signaling
Published on: August 3, 2018
Advanced glycation end-products induce tubular CTGF via TGF-beta-independent Smad3 signaling
Arthur C K Chung1, Haiyan Zhang, Yao-Zhong Kong
1Department of Medicine and Therapeutics, and Li Ka Shing Institute of Health Sciences, Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong, China.
Abstract:
Advanced glycation end-products (AGEs) can induce expression of connective tissue growth factor (CTGF), which seems to promote the development of diabetic nephropathy, but the exact signaling mechanisms that mediate this induction are unknown. Here, AGEs induced CTGF expression in tubular epithelial cells (TECs) that either lacked the TGF-beta1 gene or expressed dominant TGF-beta receptor II, demonstrating independence of TGF-beta. Furthermore, conditional knockout of the gene encoding TGF-beta receptor II from the kidney did not prevent AGE-induced renal expression of CTGF and collagen I. More specific, AGEs induced CTGF expression via the receptor for AGEs-extracellular signal-regulated kinase (RAGE-ERK)/p38 mitogen-activated protein kinase-Smad cross-talk pathway because inhibition of this pathway by several methods (anti-RAGE antibody, specific inhibitors, or dominant negative adenovirus to ERK1/2 and p38) blocked this induction. Overexpressing Smad7 abolished AGE-induced Smad3 phosphorylation and CTGF expression, demonstrating the necessity for activation of Smad signaling in this process. More important, knockdown of either Smad3 or Smad2 demonstrated that Smad3 but not Smad2 is essential for CTGF induction in response to AGEs. In conclusion, AGEs induce tubular CTGF expression via the TGF-beta-independent RAGE-ERK/p38-Smad3 cross-talk pathway. These data suggest that overexpression of Smad7 or targeting Smad3 may have therapeutic potential for diabetic nephropathy.
Insights
Advanced glycation end-products (AGEs) trigger connective tissue growth factor (CTGF) in kidney cells independently of TGF-beta. This occurs via the RAGE-ERK/p38-Smad3 pathway, suggesting Smad3 as a therapeutic target for diabetic nephropathy.
Area of Science:
- Nephrology
- Molecular Biology
- Diabetology
Background:
- Advanced glycation end-products (AGEs) are implicated in diabetic nephropathy pathogenesis.
- Connective tissue growth factor (CTGF) is upregulated in diabetic nephropathy.
- The precise signaling pathways linking AGEs to CTGF induction remain unclear.
Purpose of the Study:
- To elucidate the signaling mechanisms by which AGEs induce CTGF expression in renal tubular epithelial cells (TECs).
- To investigate the role of transforming growth factor-beta (TGF-beta) signaling in AGE-induced CTGF expression.
- To identify key molecular players in the AGEs-CTGF axis for potential therapeutic targeting.
Main Methods:
- AGEs were applied to TECs with manipulated TGF-beta signaling (gene knockout, dominant-negative receptor).
- Inhibition of the receptor for AGEs (RAGE), extracellular signal-regulated kinase (ERK), and p38 mitogen-activated protein kinase (MAPK) pathways was performed.
- Smad signaling components (Smad7, Smad2, Smad3) were modulated using overexpression or knockdown techniques.
- CTGF expression, Smad phosphorylation, and Smad2/3 involvement were assessed.
Main Results:
- AGE-induced CTGF expression in TECs was independent of TGF-beta signaling.
- Conditional knockout of TGF-beta receptor II in kidneys did not prevent AGE-induced CTGF and collagen I expression.
- Inhibition of RAGE, ERK, or p38 significantly blocked AGE-induced CTGF expression.
- Overexpression of Smad7 abolished AGE-induced Smad3 phosphorylation and CTGF upregulation.
- Knockdown of Smad3, but not Smad2, prevented CTGF induction by AGEs.
Conclusions:
- AGEs induce tubular CTGF expression through a TGF-beta-independent pathway involving RAGE, ERK/p38 MAPK, and Smad3.
- Smad3 is a critical mediator in the AGEs-induced CTGF signaling cascade.
- Targeting Smad3 or utilizing Smad7 may offer novel therapeutic strategies for diabetic nephropathy.
More Related Videos
06:54Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
Published on: October 27, 2020
07:05TGF-β-mediated Endothelial to Mesenchymal Transition (EndMT) and the Functional Assessment of EndMT Effectors using CRISPR/Cas9 Gene Editing
Published on: February 26, 2021
Related Concept Videos
TGF - β Signaling Pathway
Intracellular Signaling Affects Focal Adhesions
Some...
GPCRs Regulate Adenylyl Cylase Activity
Two...